DZ Bank reiterated their neutral rating on shares of Fresenius Medical Care AG & Co. (NYSE:FMS) in a research note published on Thursday, Borsen Zeitung reports.

Other research analysts have also issued reports about the stock. Barclays reiterated a hold rating and set a $14.00 price target on shares of MACOM Technology Solutions in a research note on Thursday, June 20th. Commerzbank reiterated a hold rating and set a $54.00 price target on shares of Fresenius Medical Care AG & Co. in a research note on Thursday, May 9th. Zacks Investment Research lowered shares of First Merchants from a hold rating to a sell rating in a research note on Monday, July 1st. Finally, Royal Bank of Canada dropped their price target on shares of from GBX 3,000 ($39.20) to GBX 2,900 ($37.89) and set an outperform rating on the stock in a research note on Thursday, June 6th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of $53.05.

NYSE FMS opened at $39.32 on Thursday. The company has a current ratio of 1.02, a quick ratio of 0.79 and a debt-to-equity ratio of 0.73. The firm has a market capitalization of $24.13 billion, a price-to-earnings ratio of 15.85, a PEG ratio of 2.79 and a beta of 1.43. Fresenius Medical Care AG & Co. has a one year low of $30.99 and a one year high of $53.40. The company has a fifty day simple moving average of $38.40.

Fresenius Medical Care AG & Co. (NYSE:FMS) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.52 by $0.07. The company had revenue of $4.13 billion for the quarter, compared to analyst estimates of $4.58 billion. Fresenius Medical Care AG & Co. had a net margin of 11.94% and a return on equity of 10.27%. Fresenius Medical Care AG & Co.’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.91 earnings per share. Research analysts anticipate that Fresenius Medical Care AG & Co. will post 2.4 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the business. Harvest Group Wealth Management LLC acquired a new position in Fresenius Medical Care AG & Co. during the first quarter worth about $29,000. Osborn Williams & Donohoe LLC acquired a new position in Fresenius Medical Care AG & Co. during the first quarter worth about $42,000. Magellan Asset Management Ltd grew its position in Fresenius Medical Care AG & Co. by 52.3% during the fourth quarter. Magellan Asset Management Ltd now owns 1,433 shares of the company’s stock worth $46,000 after buying an additional 492 shares during the period. QS Investors LLC acquired a new position in Fresenius Medical Care AG & Co. during the fourth quarter worth about $58,000. Finally, Rehmann Capital Advisory Group grew its position in Fresenius Medical Care AG & Co. by 46.7% during the first quarter. Rehmann Capital Advisory Group now owns 2,565 shares of the company’s stock worth $104,000 after buying an additional 817 shares during the period. Institutional investors own 1.45% of the company’s stock.

Fresenius Medical Care AG & Co. Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Recommended Story: Market Perform

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.